title: Erlotinib and gastric acid-reducing agents: a combination to avoid or to support?
authors.affiliation: Department of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, The Netherlands.
authors.forename: T H
authors.initials: TH
authors.lastname: Oude Munnink
authors.affiliation: Department of Pulmonary Diseases, Medisch Spectrum Twente, Enschede, The Netherlands.
authors.forename: J H
authors.initials: JH
authors.lastname: Schouwink
authors.affiliation: Department of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, The Netherlands.
authors.forename: H B B
authors.initials: HB
authors.lastname: Colen
authors.affiliation: Department of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, The Netherlands.
authors.forename: K L L
authors.initials: KL
authors.lastname: Movig
mesh_terms: D000818:Animals; D015195:Drug Design; D055808:Drug Discovery / Q000639:trends*; D004347:Drug Interactions / Q000502:physiology*; D004348:Drug Labeling / Q000639:trends*; D006801:Humans; D004364:Pharmaceutical Preparations / Q000378:metabolism*
chemical_list: D004364:Pharmaceutical Preparations